PET and MRI learning classifies prostate lesion risk
Source check: Source checked. Not independent scientific confirmation.
Finding: An ensemble of random forests combined PSMA PET and MRI features to classify 121 lesions from 52 surgical prostate-cancer patients as lower or higher risk against whole-mount pathology. Patient-separated repeated internal validation reported AUC 0.86. Additional models explored recurrence and overall risk in smaller subsets. This pilot does not establish biopsy replacement, external performance or clinical benefit.
Technology: Random-forest ensemble
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- An ensemble of nine random forests combines imaging features to classify pathology-defined lesion risk, with patient-level partitioning.
- Test and result
- Whole-mount pathology reference and repeated Monte Carlo validation that kept all lesions from each patient in one partition.
- Limitation / still unknown
- External validation and clinical utility remain unestablished; this small surgical cohort, global redundancy filtering and histology-informed lesion localization constrain generalization.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8113201/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary relevant model Methods, Results and limitations; exact primary identity and current primary PubMed correction/retraction relationships checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.